Compare Medpace Holdings Inc (MEDP) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs PulteGroup, Inc. — how do they compare? Medpace Holdings Inc trades at $601.09 (market cap $16.90B), while PulteGroup, Inc. trades at $129.06 (market cap $25.22B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PHM | |
|---|---|---|
Market Cap | $16.90B | $25.22B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $142.56 |
52-Week Low | $393.42 | $110.11 |
Enterprise Value | $16.52B | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
PulteGroup (PHM) trades at $130.05, down 2.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025 and Q1 2026. Recent news highlights operational expansion into Northwest Florida and corporate recognition as a Great Place to Work, while financials indicate solid profitability with an 11.62% net margin and a P/E of 13.53.
Outlook remains cautiously optimistic with a consensus price target of $137.20, suggesting modest upside. Risks include margin pressure from housing market affordability challenges and volatile cash flows. Institutional sentiment leans neutral with 50% hold ratings, reflecting balanced Wall Street views amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
